Fundraising FoxInkef — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Co-investorsDroia VenturesMission BiocapitalMRL Ventures FundNextech InvestRA Capital
Mosanna is a pharmaceutical company developing a non-invasive nasal spray therapy for obstructive sleep apnea (OSA) that reactivates the body's natural airway reflex to keep the upper airway open during sleep.
BiotechDigital HealthHealthtechMedical Devices
Barbara(Regulatory Affairs & Quality Assurance leadership)Kevin(Pharmaceutical Development leadership)Pranav(Head of Finance & Operations)Ben(Executive / Board)
BoardDavid White(Sleep Medicine Advisor)
Co-investorsBroadview VenturesNorwest Venture PartnersPivotal Life SciencesSupermoon CapitalForbionHTGF
Neuromodulation therapy for migraine relief.
Eindhoven, NL
Hubert Martens(Co-founder; Chief Executive Officer)Daniel Schobben(Co-founder; Chief Innovation Officer)Dr. Wim Pollet(Co-founder; Chief Medical Officer)
Co-investorsDolby Family VenturesInnovation IndustriesLevensohn Venture PartnersPanakes PartnersSHS CapitalThuja Capital
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)Miquel Vila-Perelló, Ph.D(Co-Founder & CEO)Silvia Frutos, Ph.D(Co-Founder & CTO)
Co-investorsAsabys PartnersNovartis Venture FundRoche Venture FundSanofi VenturesYsios CapitalCriteria Bio Ventures+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.